Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:65:2586-2595.
doi: 10.1016/j.matpr.2022.04.868. Epub 2022 May 11.

DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib

Chiging Sonia  1 , Th Gomti Devi  1   2 , T Karlo  1
Affiliations

DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib

Chiging Sonia et al. Mater Today Proc. 2022.

Abstract

Baricitinib is a small molecule used to treat moderate to severe rheumatoid arthritis (RA) in adults. It is an inhibitor of Janus kinase 1 and 2 (JAK1 and JAK2). It has also been repurposed as a potential treatment for Covid 19. The current study has been carried out to understand the structural and chemical properties of this molecule. The molecule is optimized by using density functional theory (DFT) method. The DFT calculations are performed using Gaussian 09 W software package. The bond lengths and bond angles between atoms in the molecules are investigated. The intramolecular interaction within the molecule is identified using the natural bond orbital (NBO) study. The atom in molecule (AIM) study is performed using Multiwfn software. All the calculations are performed at B3LYP /6311G++ (d, p) level of theory. The molecular parameters, such as first-order hyperpolarizability, HOMO-LUMO energy gap, global electrophilicity index, dipole moment, chemical potential, hardness, ionization energy and electron affinity are determined from the calculation. The molecular docking analysis of Baricitinib is also carried out against different target proteins such as 6VSB, 6W9C and 6LU7.

Keywords: AIM; Baricitinib; DFT; HOMO-LUMO; NBO.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Molecular structure of Baricitinib.
Fig. 2
Fig. 2
Frontier Molecular Orbital of Baricitinib.
Fig. 3
Fig. 3
a. Interaction of Baricitinib with 6LU7. b. Interaction of Baricitinib with 6W9C.c. Interaction of Baricitinib with 6VSB.
Fig. 3
Fig. 3
a. Interaction of Baricitinib with 6LU7. b. Interaction of Baricitinib with 6W9C.c. Interaction of Baricitinib with 6VSB.
Fig. 3
Fig. 3
a. Interaction of Baricitinib with 6LU7. b. Interaction of Baricitinib with 6W9C.c. Interaction of Baricitinib with 6VSB.
Fig. 4
Fig. 4
a. 2D representation of 6LU7-Baricitinib interaction. b. 2D representation of 6W9C-Baricitinib interaction.c. 2D representation of 6VSB-Baricitinib interaction.
Fig. 4
Fig. 4
a. 2D representation of 6LU7-Baricitinib interaction. b. 2D representation of 6W9C-Baricitinib interaction.c. 2D representation of 6VSB-Baricitinib interaction.
Fig. 4
Fig. 4
a. 2D representation of 6LU7-Baricitinib interaction. b. 2D representation of 6W9C-Baricitinib interaction.c. 2D representation of 6VSB-Baricitinib interaction.
See this image and copyright information in PMC

References

    1. Fragoulis G.E., McInnes I.B., Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology. 2019;58:i45–i54. doi: 10.1093/rheumatology/key276. - DOI - PMC - PubMed
    1. Spinelli F.R., Colbert R.A., Gadina M. JAK1: Number one in the family; number one in inflammation. Rheumatology. 2021;60:ii3-ii10. doi: 10.1093/rheumatology/keab024. - DOI - PMC - PubMed
    1. Xu J., Cai J., Chen J., Zong X.i., Wu X., Ji M., Wang P. An efficient synthesis of baricitinib. J. Chem. Res. 2016;40(4):205–208. doi: 10.3184/174751916X14569294811333. - DOI
    1. Assadiasl S., Fatahi Y., Mosharmovahed B., Mohebbi B., Nicknam M.H. Baricitinib: From Rheumatoid Arthritis to COVID-19. J. Clin. Pharmacol. 2021:1–12. doi: 10.1002/JCPH.1874. - DOI - PMC - PubMed
    1. Zhang X., Zhang Y., Qiao W., Zhang J., Qi Z. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int. Immunopharmacol. 2020;86:106749. doi: 10.1016/j.intimp.2020.106749. - DOI - PMC - PubMed

LinkOut - more resources